close

August 2022

Generic drugs

Global Generic Drugs Market Report 2022-2026

Dublin, Aug. 12, 2022 (GLOBE NEWSWIRE) — The Generic Drugs – Global Market Trajectory & Analytics report has been added to ResearchAndMarkets.com’s offer.

Global generic drug market to reach $507.8 billion by 2026

Amid the COVID-19 crisis, the global generic drug market estimated at US$402.9 billion in 2022 is expected to reach a revised size of US$507.8 billion by 2026, growing at a CAGR of 5.6% over the analysis period.

A key advantage for generic drug manufacturers is that they do not need to invest time and money in drug R&D and marketing efforts, as generic drug prices are significantly lower compared to their branded counterparts.

Generic small molecules, one of the segments analyzed in the report, is expected to grow at a CAGR of 5.2% to reach US$325.7 billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and the induced economic crisis, the growth of the biosimilars segment is readjusted to a revised CAGR of 6.3% for the next 7-year period.

This segment currently accounts for a 37.7% share of the global generic drug market. With several factors encouraging growth contributing to wider adoption, biosimilars are poised to increase their share of the global generic drug market in the coming years. The rise of biosimilars has notably reduced overall drug spending in recent years, a trend that is expected to continue for the foreseeable future.

The emergence of biosimilars in the market leads to increased competition, the next generation of biologics under development aims to improve safety, efficacy and cost factors compared to the drugs of the previous generation, which further adds to the competitive heat in the market.

The US market is estimated at $121.8 billion in 2022, while China is expected to reach $91.2 billion by 2026

The generic drug market in the United States is estimated to be worth US$121.8 billion in 2022. The country currently accounts for a 30.46% share of the global market. China, the world’s second largest economy, is expected to reach an estimated market size of US$91.2 billion in 2026 growing at a CAGR of 7.2% over the analysis period.

Other noteworthy geographic markets include Japan and Canada, each forecasting growth of 3.8% and 5% respectively over the analysis period. In Europe, Germany is expected to grow at a CAGR of approximately 4.3%, while the rest of the European market (as defined in the study) will reach US$97.6 billion by the end of the outlook period. ‘to analyse.

The market is expected to be driven by the ever increasing risk of various chronic diseases such as hypertension, obesity and diabetes. Although pharmaceutical companies continue to develop branded drugs due to the shortage of new blockbuster drugs coming to market, generic drugs are expected to continue to meet the majority of these therapeutic needs of the population, especially the elderly population. in expansion.

With the high cost of brand name drugs becoming a financial burden on people, efforts have intensified to develop cost-effective generic variants. Many branded drugs are unable to extend their exclusivity, resulting in the loss of patents and making way for affordable generics to be manufactured. Major application areas of generic drugs include cardiology, anti-infection, anti-arthritis, CNS, anti-cancer, and respiratory, among others.

Generic drugs for cardiovascular diseases currently represent the dominant segment, accounting for the majority share of the overall market. Cardiovascular diseases such as heart failure, high blood pressure, circulatory disorders, dyslipidemia, cholesterol, arrhythmias, strokes and angina pectoris are the leading causes of death worldwide.

The cardiovascular segment is expected to cover a larger portion of the global generic drugs market owing to several patent expirations of these drugs. Generic drugs for infectious diseases would gain popularity over the next few years, mainly due to the increasing number of cases around the world.

The COVID-19 pandemic has emerged as a significant growth driver for the generic drug market over the past year. As nations’ economies collapsed due to rising unemployment, the demand for cheaper substitutes for brand name drugs grew.

What’s new for 2022?

  • Global competitiveness and percentage market shares of main competitors
  • Market presence in multiple geographies – Strong/Active/Niche/Trivial
  • Peer-to-peer collaborative online interactive updates
  • Access to digital archives
  • Free updates for one year

Main topics covered:

I. METHODOLOGY

II. ABSTRACT

1. MARKET OVERVIEW

  • Generic drugs – Percentage of market share of the main global competitors in 2022 (E)
  • Progress on vaccinations, why should companies care?
  • These are times when questions abound and answers are few.
  • With the IMF’s upward revision of global GDP forecasts for 2021, most businesses are optimistic about a global economic comeback.
  • A strong economic rebound in 2021 based on pent-up demand comes as relief for struggling industries and markets
  • How has the healthcare industry been and continues to be impacted by the pandemic and what is the new normal?
  • With the COVID-19 pandemic exposing the lack of global health care preparedness, policies are increasingly focused on restarting health systems around the world: current and required health expenditure as % of GDP
  • Impact of the COVID-19 crisis on the generic drugs market
  • Demand for generic painkillers is increasing
  • A prelude to generic drugs
  • The generic drug market is poised for rapid growth
  • US dominates, Asia-Pacific shows fastest growth
  • India – An important market
  • Market constraints
  • Competition
  • Recent market activity

2. FOCUS ON CERTAIN PLAYERS (Total 42 Featured)

  • Abbott Laboratories
  • Apotex Inc.
  • ASKA Pharmaceutical Co., Ltd.
  • Aspen Pharmacare Holdings Limited
  • AstraZeneca Plc
  • Baxter International Inc.
  • Dr. Reddy’s Laboratories Limited
  • Eli Lilly and company
  • Endo International plc
  • Fresenius Kabi
  • GlaxoSmithKline Plc.
  • H.Lundbeck A/S
  • Hospira
  • Lupine Pharmaceuticals, Inc.
  • Mylan S.A.
  • Novartis International SA
  • Novo Nordisk A/S
  • F. Hoffmann-La Roche SA
  • Sandoz International GmbH
  • Sanofi-Aventis US LLC
  • STADA Arzneimittel AG
  • Sun Pharma
  • Teva Pharmaceutical Industries Ltd.

3. MARKET TRENDS AND DRIVERS

  • Patent expirations expected to expand potential generic drug market
  • Expiry of patents for certain drugs in 2020
  • Expiry of patents for certain drugs in 2021
  • Expiry of patents for certain drugs in 2022
  • Expiration of patents for certain major drugs in the United States: 2020-2022
  • High demand for pharmaceutical drugs drives demand for generic drugs
  • Cost containment measures focus on generics
  • Small molecule generics are the dominant segment
  • Increased demand for biosimilars, driven by expiring patents for key biopharmaceutical drugs
  • Expiration of patents for major biopharmaceutical drugs in the United States and Europe
  • A progressive regulatory framework accelerates product approvals and subsequently market revenue
  • Specific guidelines for biosimilars in various countries with year of publication
  • Biosimilar regulators in selected regional markets
  • US biosimilar approvals (as of February 2021)
  • Biosimilar approvals in Europe (from January 2021)
  • Rising healthcare costs drive demand for generic drugs
  • An aging population to propel demand for generic drugs
  • Growing prevalence of chronic diseases is driving demand for generic drugs
  • Global cost of chronic diseases (in billions of US dollars) for the years 2018 and 2030
  • Deaths by heart disease – Estimated percentage distribution for cardiovascular disease, ischemic heart disease, stroke and other

4. GLOBAL MARKET OUTLOOK

III. REGIONAL MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/q8s3o4

  • Global Generic Drugs Market


        
read more
Prescription drugs

High school seniors playing contact sports more likely to abuse prescription drugs in their 20s – The Hill

The story at a glance


  • Researchers collected data from more than 4,000 high school students from 2006 to 2017, then followed them for a decade to measure the relationship between sports participation and prescription drug abuse.

  • The team looked at contact, semi-contact and non-contact sports, and found that athletes are more likely than non-athletes to abuse prescription stimulants.

  • About 31% of people aged 17 to 18 reported abusing prescription drugs in the last year of the study period.

High school students who play sports are more likely than non-athletes to abuse prescription stimulants during their 20s, but those who play contact sports are even more likely than their peers to do so, according to a new study.

Researchers at the University of Michigan collected data from 4,777 12e students from 2006 to 2017 and then followed them for a decade to measure the relationship between high school sports participation and prescription drug abuse.

The team looked at contact, semi-contact and non-contact sports, and found that athletes are more likely than non-athletes to abuse prescription stimulants. They found that seniors who play contact sports are 50% more likely than those who haven’t played contact sports to abuse prescription stimulants over the next decade.

Additionally, the percentage of athletes involved in contact athletics who reported using prescription stimulants as seniors increased by 7% between the ages of 21 and 22. About 31% of people aged 17 to 18 reported abusing prescription drugs in the last year of the study period. .

America is changing faster than ever! Add Change America to your Facebook Where Twitter stream to stay up to date with the news.

The study’s lead author, Philip Veliz, an associate research professor at the University of Michigan School of Nursing, said that while opioid use among athletes in contact sports was higher , participation did not trigger any abuse.

Veliz said the abuse of opioids and stimulants has declined over the decade, “the study found that certain types of former high school athletes are at greater risk of abusing these drugs and initiate in early adulthood”.

The researchers said the study results “strengthen screenings” for monitoring drug abuse among high school athletes.

“Increased abuse of prescription stimulants after high school warrants continued monitoring into adulthood, especially in athletes,” Sean Esteban McCabe, lead author and director of DASH, the Center for the Study of Drug, Alcohol, Smoking, and Health from the University of Michigan. School of Nursing, said in the statement.

Posted on August 11, 2022

read more
Medical products

Fake test kits, seized medical products

Police show off falsely labeled ATKs, face masks and other goods seized in raids on premises in Nakhon Pathom and Nonthaburi on Thursday. (Photo: Wassayos Ngamkham)

Fake Covid-19 antigen test kits and other medical equipment, worth around 2 million baht, were seized in raids by police in Nakhon Pathom and Nonthaburi provinces on Thursday.

Teams of Consumer Protection Police Division (CPPD) officers and Food and Drug Administration (FDA) officials first searched a commercial building in tambon Naraphirom of Bang Len district in Nakhon Pathom .

They seized tens of thousands of antigen test kits (ATKs) that were falsely labeled with brand names such as Testsealabs Gica, Testsealabs Nex and Zybio, along with face masks and other products.

A woman identified only as Anusara admitted to owning the goods and the building, Central Bureau of Investigation Commissioner Lt. Gen. Jirabhob Bhuridej said.

The second raid took place at a tambon Bang Khen house in Muang district of Nonthaburi. There they seized ATKs falsely labeled as Testsealab Gia, Testsealabs Nex, Greenspring, Singclean, Seinofy, Hip, Deepblue, Humansis, Bioteke and Ustar, as well as medical gloves, oximeters and Chinese herbal products.

A woman identified only as Patyaphorn admitted to owning the house and property.

The items seized from the two locations were worth around 2 million baht in total, the CIB chief said.

The raids followed complaints that unscrupulous people were selling unapproved products falsely labeled with FDA-approved brand names.

CPPD Branch 4 Chief Pol Col Neti Wongkulab said a police investigation revealed that falsely labeled ATKs were being sold at low prices through Facebook accounts run by the two women since April. They sold ATKs for 40 to 45 baht each, cheaper than brands normally sold, Pol Col Neti said.

The police posed as customers, buying the ATKs from a shop near the site of the first raid in Nakhon Pathom. They then searched the nearby commercial building and found the same products packaged and ready for distribution. This led to the raid on the house in Nonthaburi.

Pol Col Neti said the next step would be to arrest the Chinese national who allegedly supplied these counterfeit products. Investigators believed at least four people were involved.

FDA Secretary General Paisarn Dunkum said oximeters and ATKs are medical devices. Tampering with medical equipment affects quality and safety and poses a danger to medical staff and patients.

Tampering with medical equipment is punishable by up to 10 years in prison and/or a fine of one million baht, Dr Paisarn said.

read more
Medical supplies

Key to Automated Payments for Medical Supplies

PYMNTS recently met with two of the players in the health sector.

On the purchase side, Huntington Healthwhich is affiliated with the Cedars-Sinai Health System in California, shared how faster and more efficient delivery of vital medical supplies is occurring despite limited supplies and other recently exposed system weaknesses.

From a financial point of view, American Express shared his perspective on the history, status quo and future of digitization and automation of payments in the healthcare sector, which accounts for nearly 20% of gross domestic product (GDP).

Read more: B2B Payments in Healthcare Tracker®

The buy side

Like many other health systems, Huntington Health faces payment issues when purchasing medical supplies, seeking faster and more efficient payment processes instead. Embracing technology and trusted financial partnerships can ease friction.

Huntington buys about $100 million worth of supplies and equipment a year – even bandages. The pandemic has tested purchases with a mad rush for specialized types of equipment, such as N95 masks and ventilators, which are not normally stocked in bulk or available in large quantities from medical supply suppliers. trusted or even government stocks.

The pandemic presented a unique day-to-day scenario where the hospital needed to be prepared to write a check or quickly transfer money outside of its normal purchasing systems, which required manual billing, shipping, and Accounts Payable (AP) .

Slowly, this is changing as hospitals are beginning to see the benefits of using enterprise resource planning (ERP) solutions to streamline different processes and work towards achieving overall organizational efficiency. Still, it takes time to implement new technologies in large healthcare organizations, and Huntington is about three years away from full adoption.

The use of electronic payments is also growing. The number of ACH healthcare payments in the second quarter of 2022 was 113.7 million, an increase of 5.3% compared to the 108 million ACH healthcare payments in the second quarter of 2021, according at Nasha.

Yet while providers prefer ACH payments and direct deposits, their customers are making up to 85% of their payments by check or other paper-based methods, as shown in the B2B Payments in Healthcare Tracker, a collaboration between PYMNTS and American Express.

The healthcare industry is also facing staffing shortages in many different disciplines. Huntington is working to adopt artificial intelligence and robotics technology that can help reduce the need for human effort.

The Financial Sector Perspective

American Express believes that automation can improve medical supplies procurement and supplier relationships. The shape of things to come implies a future in which automation will continue as procurement ensures supply chain efficiency.

Healthcare is particularly sensitive to pandemic issues, and many back-office employees are still inclined to work from home. Digital access to physical assets, such as ledgers, invoices and checks, widely adopted during shutdowns, continues to enable this trend, helping to address labor shortages while reducing workforces by maximizing efficiency and effectiveness.

Remote back office work also frees up facility space for clinical and wellness revenue generating uses.

See also: Health accounts for 20% of GDP which desperately needs payment efficiency

Automated billing creates a backbone of supply support to deliver critical medical supplies on time. Fully automated AP and Accounts Receivable (AR) processes with electronic invoicing can eliminate friction by correcting discrepancies.

Hospitals have embraced AP automation solutions, which conversely have vendors looking for AR solutions and payment portals to maximize receivable collection rates and treasury applications while using solutions supply chain finance.

The challenges of travel

The journey to the promised land necessarily requires a trek through the desert. Supply is challenged by a myriad of factors, especially when visibility into hospital inventory is poor.

Internally, data management can be difficult when working on decentralized legacy systems. Teams that can still take very manual steps to place orders will cause delivery delays, further blurring visibility into inventory levels, orders, and delivery schedules.

Externally, ongoing changes in regulatory requirements are impacting on-demand medical supplies that need to be stocked. Additional tension occurs when demand spikes, bidding processes lack transparency, and supply chain procurement logistics come to a halt.

Concentration remains a problem. While nothing focuses the mind quite as wonderfully as the prospect of a pandemic, hospitals and healthcare systems are still focused on other priorities, including clinics, compliance, revenue cycle management, and consolidation. after the merger and acquisition.

A common goal

Huntington looks forward to the time when direct payments to overseas suppliers can be made by machines that can instantly account for supply chain delays. By using pre-authorized payment methods such as virtual cards, machines can ensure a steady flow of supplies and pay for them in local currency.

Meanwhile, American Express envisions the convergence of buyers and suppliers under the umbrella of automation. FinTechs and financial institutions will be instrumental in providing the healthcare industry with the payment digitization and automation solutions it needs to succeed in this matter of life and death.

For all PYMNTS B2B coverage, subscribe daily B2B Newsletter.

——————————

NEW PYMNTS SURVEY FINDS 3 IN 4 CONSUMERS HAVING HIGH DEMAND FOR SUPER APPS

About: Results from PYMNTS’ new study, “The Super App Shift: How Consumers Want To Save, Shop And Spend In The Connected Economy,” a collaboration with PayPal, analyzed responses from 9,904 consumers in Australia, Germany, UK and USA. and showed strong demand for one super multi-functional app rather than using dozens of individual apps.

read more
Prescription drugs

Passage of the Cut Inflation Act includes cutting the cost of prescription drugs

AARP in the Virgin Islands

AARP – in the Virgin Islands shares a statement released by AARP CEO Jo Ann Jenkins following the historic vote to pass the Cut Inflation Act. The message was released on August 7 immediately after the Senate vote. The Senate voted to pass the Cut Inflation Act of 2022, a bill that includes several key provisions to drive down prescription drug prices. AARP thanked all of the senators who voted to support this essential legislation and move closer to real relief for seniors.

The Inflation Reduction Act includes key AARP priorities that will go a long way in reducing drug prices and out-of-pocket costs. AARP fought for provisions in the bill that:

  • Finally allow Medicare to negotiate drug prices
  • Cap annual prescription drug spending in Medicare Part D at $2,000
  • Hold drug companies accountable when they raise drug prices faster than the rate of inflation, and
  • Cap the insulin co-pay to a maximum of $35 per month in Part D.

Jo Ann Jenkins, executive director of AARP, released a statement in reaction to the Senate vote:

“Since AARP’s inception, we have fought to ensure seniors have access to affordable health care, including prescription drugs. And we’ve worked for nearly two decades to allow Medicare to negotiate the price it pays for drugs. Thanks to today’s historic vote in the Senate, millions of Americans over 50 are one step closer

to real relief from runaway prescription drug prices. This bill will save Medicare hundreds of billions of dollars and give seniors peace of mind knowing there is an annual limit on what they have to pay out of pocket for drugs. Lowering prescription drug prices is a top priority for Americans, with more than 80% of people from all political parties supporting the measure. We thank all senators who voted today to lower drug prices.

“We are also thrilled that the bill will keep health insurance affordable for millions of Americans who buy their coverage in the market, especially consumers between the ages of 50 and 64, including more than one million got more affordable options.

Printable, PDF and email version
read more
Medical products

Growing medical device maker with 110 new jobs in Houston County

Mark Fellows, vice president of GRI-APS, said the additional 110 jobs in Houston County will increase over the next 90 days.

“These growth plans for Global Resources International and Advanced Product Solutions represent a significant development for the Wiregrass region,” said Greg Canfield, Secretary of the Alabama Department of Commerce.

“This expansion will enhance domestic production of much-needed products for Alabama and nationwide customers, while strengthening GRI-APS’ presence in Wiregrass.”

GROWTH PLANS

In a joint statement, Dothan Mayor Mark Saliba and Houston County Commission Chairman Mark Culver praised GRI-APS’ continued investment and said they are “incredible examples of partners community trade”.

Columbia Mayor Cas Haddock said the GRI-APS project is a “breath of fresh air” for the Houston County community of 800.

“We are grateful that they chose Columbia, Alabama for this sophisticated operation,” he added.

GRI, headquartered in Flowery Branch, Georgia, is a privately held manufacturing and supply company specializing in the design, manufacture, sterilization and distribution of products for the healthcare, medical and medical markets. industry and animal care.

A long-standing GRI affiliate, based in Ashland, Alabama Eastern Technologies Inc.. produces protective equipment for workers in industries such as nuclear power, chemicals and defence. (Learn more about ETI’s efforts at the start of the pandemic.)

A broad partnership of state and local agencies supported the project. At the state level, these include the governor’s office; the Alabama Department of Commerce; AIDT, the state’s main workforce development agency; and Southeastern Alabama works.

The City of Dothan, Houston County Commission, City of Columbia, Dothan Industrial Development Council, and Dothan Chamber/Grow Dothan Development Team also supported the project, as did Dothan Utilities, Alabama Municipal Electric Authority. and Southeast Gas.

read more
Medical supplies

Global Medical Supplies Market Report 2022, Trends and Opportunities to 2030 – Shanghaiist

published by researchreports.xyz

Comprehensive analyzes of the fastest growing medical supplies market provide insights that help stakeholders identify opportunities and challenges. The 2022 markets could be another big year for medical supplies. This report provides an overview of the company’s activities and financial situation (a company profile is required if you want to raise capital or attract investors), recent developments (mergers and acquisitions) and recent SWOT analyses. This report focuses on the medical supplies market over the assessment period 2030. The report also provides an analysis of the growth of the medical supplies market which includes Porter’s five factor analysis and analysis of the Supply Chain.

Click here to access the sample report: researchreports.xyz/Request-For-Sample-Report?/Medical-Supplies&id=9403

This Medical Supplies analysis report also provides in-depth insights into other upcoming trends and challenges that will have a tremendous effect on the growth of the market. Get detailed insights into trends and challenges, which will help businesses assess and develop strategies for growth.

Who are the main suppliers of medical supplies?

Medtronic plc (Ireland), Cardinal Health, Inc. (USA), Becton, Dickinson and Company (USA), Johnson & Johnson (USA), B. Braun (Germany), Boston Scientific Corporation (USA), USA), Thermo Fisher Scientific (USA), Baxter International Inc. (USA), Halyard (USA), 3M (USA)

Detailed segmentation:

By TypeDiagnostic ProductsDialysis ConsumablesTrauma ConsumablesRadiation Related ConsumablesInfusion Related ProductsBy ApplicationUrologyWound CareRadiologyAnesthesiaSterilizationCardiologyOphthalmologyOther ApplicationsBy End UsersHospitalsClinicsOtherBy Distribution ChannelOnline ChannelOffline Channel

Get 30-50% off various types of licenses when buying it now (use corporate email id for higher priority) @researchreports.xyz/Check-Discount-On-Report?/ Medical-Supplies&id=9403

Competitive landscape highlighting important parameters players are gaining with market shifts and developments:

• % market share, SWOT analysis, segment revenue for each company profile.
• Overview of the activity and classification of the products or services.
• Latest developments (product launches, technological advances, manufacturing, expansion plans and research and development)
• Matrix of products or services.
• Capacity, consumption and production of players.

Quantitative data:

1. Market Revenue and Growth Rate by Type (Historical and Forecast)
2. Market revenue and growth rate by application, such as food, beverage, pharmaceutical, industrial & chemical, cosmetic & personal care, agriculture, etc.
3. Market Revenue, Growth Rate, Volume, Type and Application by Each Country (Historical and Forecast)
4. Revenue, volume and annual growth rate per player (reference year).

Qualitative data:

It contains sections related to market dynamics and trending factors that are influencing or driving market growth. To list some names of the sections covered:

• Overview of the global medical supplies industry.
• Global market growth drivers, opportunities and restraints.
• Gaps and opportunities in the medical supplies market
• Market entropy (suppression of aggressiveness and strategic moves by industry players).
• Analysis of Porter’s five forces (potential new market entrants, competitive competitors, alternative customers and products).
• PESTLE analysis (360 degree view of the market).
• Analysis of trademarks and patents.
• Competitive analysis (of each player and manufacturer featured in the report) SWOT analysis display).
• Medical supplies market developments and insights innovations, and new product or service launches.
• Investment and project feasibility study.

We also offer customization of reports based on specific customer requirements:

– Free country-level analysis for the 5 countries of your choice.
– Free competitive analysis of 5 key market players.
– 40 hours of free analysis to cover any other data point.

For a custom report, click @ researchreports.xyz/Reports-Description-And-Details?/Medical-Supplies&id=9403

All of the reports we list tracked the impact of COVID-19. The upstream and downstream of the entire supply chain were taken into account during this operation. Additionally, where possible, we will provide an additional COVID-19 update supplement/report to the third quarter report, please check with the sales team.

About Us:

researchreports.xyz is the credible source for getting the research reports that will provide you with the direction your business needs. The market is changing rapidly with the continuous expansion of the industry. Technological advancements have provided today’s businesses with multi-faceted benefits driving daily economic changes. Thus, it is very important for a business to understand the patterns of market movements in order to better strategize. An effective strategy gives companies a head start in planning and an advantage over their competitors.

Contact us

Research reports

Phone (UK): +44 141 628 5998

Email: [email protected]

Web: https://www.researchreports.xyz

read more
Prescription drugs

Hyperlipidemia Prescription Drugs Market Research Report 2022

Global Prescription Drugs for Hyperlipidemia Market is expected to grow at a CAGR of 14.5% to reach xx Million USD through 2029

Prescription drugs for hyperlipidemia Market overview

The Prescription Drugs for Hyperlipidemia market research report includes all the necessary details. By providing accurate data to its clients, it helps them make important decisions and gives market forecasts. This study, which combines primary and secondary research, provides market size, share, trends and forecasts for important segments and sub-segments. This market research monitors all the latest developments and changes in the industry. It provides information on the obstacles encountered when starting a business and offers advice on how to deal with impending difficulties.

Browse the full report at:

https://pharmaresearchconsulting.com/reports/hyperlipidemia-prescription-drugs-market-global-growth-trends-and-forecast-2022-2029-by-type-hmg-coa-reductase-inhibitors-fibric-acid-derivatives- nicotinic-acid-by-hospital-clinical-application-and-by-regions

Report scope

The research analysis of the Global Prescription Drugs for Hyperlipidemia Market takes a close look at the market size, trends, and potential opportunities. By offering in-depth details of technology expenditure for the projection year, this research provides a unique perspective on the global Prescription Hyperlipidemia Drugs market across various categories. Clients can learn more about the potential and limitations of the industry by reading the study on Global Prescription Drugs for Hyperlipidemia Market. The study discusses in detail a number of factors that have been identified as influencing the growth trajectory of the market. The issues facing the market are also identified in the study.

Profile of key companies in the report:

Amgen, are Eli Lilly, GlaxoSmithKline Pharmaceuticals, Isis Pharmaceuticals, Merck, Dr. Reddy’s Laboratories, Immuron Limited, Esperion Therapeutics and Pfizer, Formac Pharmaceuticals and others.

Prescription drugs for hyperlipidemia Market segmentation :

By Type, it is segmented into

HMG COA reductase inhibitors

Fibric acid derivatives

nicotinic acid

Bile acid sequestering agents

Cholesterol absorption inhibitors

Combination drug therapy

By Application, it is segmented into

Hospital

Clinical

Others

Regional Analysis Of Prescription Drugs For Hyperlipidemia Market

The research mentions the regional scope of the market, mainly focusing on the following areas:

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia, etc.)

Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa)

Points covered in the report

It includes a detailed description of each company. Along with these factors, the study also covers their capacity, production, price, revenue, cost, gross margin, sales volume, revenue, consumption, growth rate, import , their exports, supply, future plans and technological advancements. This study forecast and reviewed data for the past 12 years.

There is a detailed discussion of the market growth factors, along with a detailed explanation of each of the market end users.

The data and information is broken down by market player, region, type, application etc. and also by custom

Prescription drugs for hyperlipidemia Market Players and Competitor Analysis:

The research includes company profile, product specifications, production/sales capacity, revenue, price and gross margin 2022-2029, and sales by type for major market players.

Regional and global market research Global and regional market status and outlook for 2022-2029 are included in the report. The report also includes breakdown information for each region and country it covers. identifying the number of sales and revenue projections, as well as its production, consumption, imports and exports.

Market analysis by product type: The study covers the majority of product types used in the Prescription Drugs for Hyperlipidemia market, along with product details for each major player, volume and sales by volume and value.

Market analysis by type of application: The market is further subdivided into numerous key applications of its industry based on the Prescription Hyperlipidemia Drugs market and its applications. It offers market size, CAGR, and forecast information for each application in the industry.

Market trends: Two major market trends are the escalation of competition and continuous innovation.

Main highlights of the Prescription drugs for hyperlipidemia Market report:

– Overall assessment of the parent market
– Evolution of the significant aspects of the market
– Industry-wide survey of market segments
– Assessment of the value and volume of the market over the past, present and forecast years (2022-2029)
– Market share assessment
– Tactical approaches from market leaders
– Money-making strategies to help companies strengthen their position in the market

Click the link for a free sample copy of the report:

https://pharmaresearchconsulting.com/reports/veterinary-therapeutics-market-global-growth-trends-and-forecast-2022-2029-by-type-by-distribution-channel-by-regions-by-key-players- zoetis-inc-merck-animal-health-elanco-animal-health-boehringer-ingelheim-gmbh/request

Contents:

Chapter 1: Introduction, Market Driver Product Research and Research Objectives Scope of Prescription Drugs for Hyperlipidemia Market

Chapter 2: Exclusive Summary – Basic Information on the Prescription Drugs for Hyperlipidemia Market.

Chapter 3: Revealing Market Dynamics – Drivers, Trends and Challenges

Chapter 4: Prescription drugs for hyperlipidemia Introducing Porters Five Forces Market Factor Analysis, Supply/Value Chain, Pestel Analysis, Market Entropy, Patent/Trademark Analysis.

Chapter 5: View by Type, End User and Region 2022-2029

Chapter 6: Evaluating Hyperlipidemia Prescription Drugs Market Key Manufacturers Including Competitive Landscape and Company Profiles

Chapter 7: To assess the market by segments, countries and manufacturers, with revenue sharing and sales by key countries for these various regions.

Chapters 8 and 9: Appendix, methodology and data source display

About Us

Pharma Research Consulting (An Improve Digital Consultancy Pvt Ltd Group Company) provides

syndicated market research reports to industries, organizations or even individuals to help them

their decision-making process

Contact us: –

Phone number+1 (704) 266-3234 | [email protected]

read more
Generic drugs

Generic Inhalation and Nasal Spray Market Segmentations, Trends, Share, Size, Major Key Players and Forecast to 2030 – Instant Interview

The Generic Inhalation and Nasal Spray market report is provided here in USD Million. The report will provide insightful data related to the growth rates represented in terms of CAGR % over the projected years. The report will discuss which strategies to adopt after COVID-19, along with a comprehensive analysis of the growth factors, types, applications, impending challenges, competitive landscape, key trends to watch, PEST analysis and overall market dynamics. The main objective of the Inhalation And Nasal Spray Generic Drugs market report is to analyze the impact of COVID-19 on the market and the opportunities to be exploited in the future. The Generic Inhalation and Nasal Spray Drugs Market study examines the market performance for the top 20 countries and understands the growth potential in these countries.
For More Details, Download Free Sample of Generic Inhalation and Nasal Spray Drugs Market: https://healthcaremarketreports.com/sample-request/inhalation-and-nasal-spray-generic-drugs-market/170/

Global Generic Inhalation and Nasal Spray Drugs Market: Major Key Players
Novartis AG (Sandoz International GmbH)
cipla ltd.
Allergan AG
Nephron Pharmaceutical Company
Ranbaxy Laboratories Ltd.
Teva Pharmaceutical Industries Ltd.
Beximco Pharmaceuticals
Mylan AG
Roxane Laboratories, Inc.

Global Generic Inhalation and Nasal Spray Drugs Market by Types
Generic Nasal Spray Drugs
Generic inhaled drugs

Global Generic Drugs for Inhalation and Nasal Spray Market: By Applications
Asthma
COPD
Allergic rhinitis

Global Generic Drugs for Inhalation and Nasal Spray Market by Country
United States
Canada
Germany
UK
France
Italy
Spain
Russia
China
Japan
South Korea
Australia
Thailand
Brazil
Argentina
Chile
South Africa
Egypt
United Arab Emirates
Saudi Arabia

The global healthcare industry has been growing at a CAGR of around 5% and is expected to produce even more in the future. The healthcare industry is growing at a steady pace and is expected to move up the growth ladder in the future. The healthcare sector consists of several main areas including healthcare services and facilities, hospital supplies, medical equipment, pharmaceuticals and drugs and we provide comprehensive information on these sectors with utmost accuracy. .

Healthcare organizations are now working in a dynamic environment, undergoing seismic transformations following the introduction of innovative medical treatments and increased use of the internet. This, combined with unrivaled online access to incredible amounts of information, has made astute patients more cautious. As a result, the demand for smart, affordable and personalized healthcare services has exploded. The COVID-19 pandemic has further led to an increase in demand for healthcare and related products and services, further bolstering the performance of the entire healthcare industry.
Our specialized reports offer information tailored to the unique needs of all important stakeholders. Our reports come with market assessments that provide our clients with useful information on market size, current competition, and other factors. The reports also estimate the burden of common and unusual medical conditions based on prevalence and cost of care. The reports also include an executive-level market plan and valuable insights to help establish effective expansion plans. Healthcare reports also provide an in-depth look at the research and development landscape of a market. These data pointers and analytics provide in-depth research of pipeline product distribution by clinical trial stage, therapeutic region, indication and other factors.

Buy Direct Inhalation and Nasal Spray Generic Drugs Market Research Report: https://healthcaremarketreports.com/purchase/inhalation-and-nasal-spray-generic-drugs-market/170/

FAQs
• What is the driving factor for the growth of the Inhalation And Nasal Spray Generic Drugs market?
• What impact will COVID-19 pandemic have on demand and consumption for the Inhalation And Nasal Spray Generic Drugs Market?
• What is the major application area of ​​the Inhalation And Nasal Spray Generic Drugs market?
• Who are the manufacturers of generic inhalers and nasal sprays in the world?
• Which geographical area is predominant in the Inhalation And Nasal Spray Generic Drugs market?
• Who are the leading industry players in the Generic Inhalation and Nasal Spray Drugs Market?

About Us:
The healthcare industry is certainly facing disruption, with global economies placing great importance on individual health. In this scenario, we expect our customers to get deep insights to propel their innovations in the right direction. We have closely followed the changes and modifications that occur in the field of health. According to our understanding, these alterations are active and unexampled.

read more
Prescription drugs

Senate lawmaker weakens plan of Senate prescription drug bill, climate change initiatives remain intact

WASHINGTON– On Saturday, the Senate congressman struck a blow to the Democrats’ plan to cut drug prices, but left the rest of their sprawling economic bill largely untouched as party leaders geared up for early votes on a package containing many of President Joe Biden’s major national goals.

Elizabeth MacDonough, the nonpartisan arbiter of the chamber rules, said lawmakers must remove language imposing stiff penalties on drugmakers who raise prices above inflation in the private insurance market. . These were the bill’s main rate protections for the roughly 180 million people whose health coverage comes from private insurance, either through work or purchased on their own.

Other important provisions remained intact, including giving Medicare the power to negotiate what it pays for pharmaceuticals for its 64 million elderly beneficiaries, a longtime goal for Democrats. Penalties on manufacturers for overshooting inflation would apply to drugs sold to Medicare, and there is a $2,000 annual cap on free drug and vaccine costs for Medicare beneficiaries.

RELATED | Democrats say they have reached an agreement on the climate and the tax bill

His decisions came as Democrats planned to begin votes in the Senate on Saturday on their sweeping agenda covering climate change, energy, health care costs, taxes and even deficit reduction. Party leaders said they believe they have the unity they will need to push the legislation through the Senate 50-50, with Vice President Kamala Harris’s deciding vote and a strong Republican opposition.

“This is a major victory for the American people,” Senate Majority Leader Chuck Schumer, DN.Y., said of the bill, which both parties are using in their election campaigns to blame the worst period of inflation in four years. decades. “And a sad commentary on the Republican Party as it actively fights cost-cutting provisions for the American family.”

In response, Senate Minority Leader Mitch McConnell, R-Ky., said Democrats are “misinterpreting the outrage of the American people as a mandate for another reckless fiscal and spending spree.” He said Democrats “have already robbed American families once through inflation and now their solution is to rob American families a second time.”

Abandoning penalties on drugmakers reduces incentives for pharmaceutical companies to restrict what they charge, which increases costs for patients.

RELATED | PACT Act: Senate passes healthcare for veterans exposed to toxic burning stoves amid protests

Erasing that language will reduce the $288 billion in 10-year savings that Democrats’ blanket drug restrictions were meant to generate — a reduction of perhaps tens of billions of dollars, analysts say.

Schumer said MacDonough’s private insurance price cap decision was “an unfortunate decision.” But he said the lingering drug pricing language represented “a major victory for the American people” and that the overall bill “remains largely intact.”

The decision followed a 10-day period in which Democrats resurrected key elements of Biden’s agenda that seemed dead. In quick deals with the Democrats’ two most unpredictable senators — first conservative Joe Manchin of West Virginia and then Arizona centrist Kyrsten Sinema — Schumer pieced together a vast package that, although a fraction of earlier versions bigger than Manchin has derailed, would give the party a feat in the context of the legislative elections this fall.

The parliamentarian also signed a levy on excess emissions of methane, a potent contributor of greenhouse gases, from oil and gas drilling. She also left environmental grants to minority communities and other carbon reduction initiatives, said Senate Environment and Public Works Committee Chairman Thomas Carper, D-Del.

She approved a provision requiring union-wide wages to be paid if energy efficiency projects are to qualify for tax credits, and another that would limit electric vehicle tax credits to cars and trucks. assembled in the USA.

The blanket measure faces unanimous Republican opposition. But assuming Democrats fight an unbroken “vote-a-rama” of amendments — many of which are designed by Republicans to derail the measure — they should be able to force the measure through the Senate.

The switch to the House could take place when that House returns briefly from recess on Friday.

“What the vote-a-rama will look like. It’ll be like hell,” Sen. Lindsey Graham of South Carolina, the top Republican on the Senate Budget Committee, said Friday of the approaching GOP amendments. He said that by supporting the Democratic bill, Manchin and Sinema are “strengthening legislation that will make life harder for the average person” by forcing energy costs with tax increases and making it harder for businesses to hire workers.

The bill proposes spending and tax incentives to switch to cleaner fuels and support coal with help to reduce carbon emissions. The expiration of subsidies that help millions pay private insurance premiums would be extended by three years, and $4 billion is earmarked to help Western states fight drought.

There would be a new minimum tax of 15% on certain corporations that earn more than $1 billion a year but pay significantly less than the current corporate tax of 21%. There would also be a 1% tax on companies buying back their own shares, traded after Sinema refused to back higher taxes for private equity firm executives and hedge fund managers. The IRS budget would be inflated to strengthen its tax collections.

While the final costs of the bill are still being determined, overall it would spend more than $300 billion over 10 years to slow climate change, which analysts say would be the country’s biggest investment in this. effort, and billions more for health care. This would raise more than $700 billion in taxes and government drug cost savings, leaving about $300 billion for deficit reduction – a modest portion of projected 10-year deficits of several trillions of dollars. dollars.

Democrats are using special procedures that would allow them to pass the measure without having to achieve the 60-vote majority that legislation often needs in the Senate.

It is the parliamentarian’s job to decide whether parts of the legislation should be dropped for violating these rules, which include the requirement that the provisions are intended primarily to affect the federal budget, not to impose new policy.

Copyright © 2022 by The Associated Press. All rights reserved.

read more
Generic drugs

Global generic drug market to reach $631.58 billion by 2027

DUBLIN, August 5, 2022 /PRNewswire/ — The report “Global Generic Drugs Market (2022-2027) by Category, Applications, End User, Geography, Competitive Analysis and Covid-19 Impact with Ansoff Analysis” has been added to from ResearchAndMarkets.com offer.

The global generic drug market is estimated at $374.14 billion in 2022 and should reach $631.58 billion by 2027 at a CAGR of 11.04%.

Market segmentation

The global generic drugs market is segmented on the basis of category, applications, end-user, and geography.

  • By category, the market is categorized into biosimilars and small molecule generics.
  • By applications, the market is categorized into Anti-Arthritis Drugs, Anti-Cancer Drugs, Anti-Infection Drugs, Cardiovascular Drugs, Central Nervous System Drugs, and Respiratory Drugs.
  • By end-user, the market is categorized into pharmacies, hospitals, pharmacies, private clinics, and retail pharmacies.
  • By geography, the market is categorized into Americas, Europe, Middle East & Africa and Asia Pacific.

Countries studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United StatesRest of the Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Swiss, UKRest of Europe)
  • Middle East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emiratesrest of the MEA)
  • Asia Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, TaiwanRest of Asia Pacific)

Competitive quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and assess the position of companies based on their industry position score and market performance score. The tool uses various factors to classify players into four categories. Some of these factors considered for analysis are financial performance over the past 3 years, growth strategies, innovation score, new product launches, investments, market share growth, etc

Ansoff analysis

The report presents a detailed analysis of the Ansoff matrix for the global generic drugs market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design business growth strategies. The matrix can be used to assess approaches in four strategies viz. Market development, market penetration, product development and diversification. The matrix is ​​also used for risk analysis to understand the risk associated with each approach. The analyst analyzes the global generic drugs market using the Ansoff Matrix to provide the best approaches a company can take to improve its position in the market. Based on the SWOT analysis done on the industry and industry players, the analyst has designed appropriate strategies for market growth.

Why buy this report?

  • The report offers a comprehensive assessment of the global generic drugs market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and market size projections. Projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The main research is done through interviews, surveys and observations of renowned personnel in the industry.
  • The report includes in-depth market analysis using Porter’s 5 forces model and Ansoff’s matrix. Additionally, the impact of Covid-19 on the market is also presented in the report.
  • The report also includes the regulatory scenario in the industry, which will help you to make an informed decision. The report discusses the major regulatory bodies and major rules and regulations imposed on this industry across various geographies.
  • The report also contains competitive analysis using Positioning Quadrants, the analyst’s proprietary competitive positioning tool.

Report Highlights:

  • A comprehensive analysis of the market, including the parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current and projected market size based on value and volume
  • Market shares and strategies of the main players
  • Recommendations for companies to strengthen their presence in the market

Market dynamics

Drivers

  • Low cost of generic drugs compared to brand name drugs
  • Robust M&A activity in the generic drug market
  • Growing incidences of chronic diseases

Constraints

  • Strong commercialization of brand name drugs eclipses generic drugs

Opportunities

  • 3D manufacturing technology boosts
  • Increase collaboration on generic drug research

Challenges

  • Inactive ingredients or excipients are different

Main topics covered:

1 Description of the report

2 Research methodology

3 Executive summary

4 Market dynamics

5 Market Analysis

6 Global Generic Drugs Market, by Category

7 Global Generic Drugs Market, by Applications

8 Global Generic Drugs Market, By End User

9 Americas Generic Drugs Market

ten Europe Generic drugs market

11 Middle East and africa Generic drugs market

12 APAC Generic Drugs Market

13 Competitive landscape

14 company profiles

15 Appendix

Companies cited

  • Abbott Healthcare Pvt. ltd.
  • Allergan PLC
  • Amneal Pharmaceuticals, Inc.
  • Aspen Pharmacare Holdings Ltd.
  • Aurobindo Pharma Ltd.
  • Baxter International Inc.
  • Cipla inc.
  • Eli Lilly and company
  • Endo Pharmaceuticals Inc.
  • Fresenius medical care
  • GSK-API
  • Apotex Inc.
  • Lupine Ltd.
  • Mylan AG
  • Novartis International
  • Pfizer Inc.
  • Sandoz International GmbH
  • STADA Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/7zc1v9

Media Contact:

Research and Markets
Laura Woodsenior
[email protected]

For EST office hours, call +1-917-300-0470
For USA/CAN call toll free +1-800-526-8630
For GMT office hours call +353-1-416-8900

US Fax: 646-607-1907
Fax (outside the US): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets

read more
Medical supplies

Medical supplies market worth $163.5 billion by 2027 –

Chicago, Aug. 05, 2022 (GLOBE NEWSWIRE) — The medical supplies market is expected to grow from USD 138.4 billion in 2022 to USD 163.5 billion by 2027, at a CAGR of 3.4% from 2022 to 2027 according to a new report from MarketsandMarkets™. The growth of this market can be attributed to the expanding geriatric population, increasing investment in research, high volume of surgical procedures, and high prevalence of chronic diseases.

Download the PDF brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64344238

Browse the in-depth table of contents at “Medical supplies market
174 – Tables
39 – Numbers
281 – Pages

In 2021, intubation and ventilation supplies accounted for the largest share of the medical supplies market, by type.

By Type, the medical supplies market is segmented into diagnostic supplies, dialysis consumables, wound care consumables, radiology consumables, disinfectants, infusion and injectable supplies, intubation and ventilation supplies, personal protective equipment , sterilization consumables, catheters, sleep apnea consumables and other medical equipment. In. The intubation and ventilation supplies segment held the highest share, which is attributed to its massive demand amid the novel coronavirus outbreak. The overwhelming influx of COVID-19 patients has created a huge demand for intubation and ventilation supplies which has fueled the market share.

By other application accounted for the largest market share in 2021.

Based on application, the medical supplies market is segmented into urology, wound care, radiology, respiratory, infection control, cardiology, IVD and other applications. The other application segment held the largest share. Other application areas include dentistry, neurology, gastroenterology, orthopedics and waste management applications. The segment market share is driven by high number of surgeries and increasing prevalence of neurological disorders, dental diseases, gastrointestinal disorders and others.

By end user, hospitals accounted for the largest market share in 2021.

Based on end-user, the market is segmented into hospitals, clinics/doctor’s offices, and other end-users. In 2021, the hospital segment accounted for the largest market share. This can be attributed to increased investment in healthcare and state-of-the-art infrastructure.

Request sample pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=64344238

North America was the largest regional market for the medical supplies market in 2021.

The medical supplies market is segmented into five major regions, namely North America, Europe, Asia Pacific and Rest of the World. North America held the largest market share in 2021, followed by Europe. The largest North America market share is driven by high incidence of strong presence of industry players, high prevalence of chronic and infectious diseases and advanced healthcare infrastructure in the region.

Some of the major players operating in the medical supplies market are Medtronic plc (Ireland), Cardinal Health (US), BD (US), Johnson & Johnson, Inc. (US), B. Braun Melsungen AG (Germany), Boston Scientific Corporation (US ), Thermo Fisher Scientific, Inc. (USA), Baxter (USA), 3M (USA), Smith & Nephew (Ireland), Convatec Inc. (UK), Abbott (USA) , Cook Medical (USA), Merit Medical Systems (USA), Stryker (USA), Terumo Corporation (Japan), Teleflex Incorporated (USA), Fresenius Medical Care AG & Co. KGaA (Germany) , Coloplast Group (Denmark), Hamilton Medical (Switzerland), ACell, Inc. (USA), Invacare Corporation (USA), Medline Industries, LP. (USA), DeRoyal Industries, Inc. (USA), Shenzhen MedRena Biotech Co., Ltd. (China), Kerecis (USA) and Whiteley (Australia).

Get 10% free customization on this report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=64344238

Browse the adjacent market: Research reports and advice on the medical device market

Related reports:

Infection Control Market by product [Sterilization (Steam, Hydrogen Peroxide, EtO), Disinfection (Wipes, Liquids, Disinfectors), Services, E-beam, Face Masks]End user (Hospitals, Pharmaceutical companies) (2022 – 2026)


        
read more
Medical products

Inequalities in access to COVID-19 medical products persist as corporate power expands : Peoples Dispatch

Cases of COVID-19 persist around the world, raising particular concern in regions with low immunization rates due to unequal access to vaccines. As the pandemic continues, analyzes of the global response continue to underscore the dangers of prevailing multi-partisan campaigns. One of the latest of these analyzes is a report published by Transnational Institute and Friends of the Earth International in July. It examines how transnational corporations (TNCs) seized the opportunity to gain more power over international institutions and expand markets during the COVID-19 pandemic.

During the launch of the report, Lauren Paremoer of the People’s Health Movement pointed out that the capture of the multilateral system by TNCs and private philanthropies was already underway before the pandemic, but extraordinary circumstances have led to an unforeseen expansion. In the report itself, Harris Gleckman, former head of the New York office of the United Nations (UN) Conference on Trade and Development, highlights how a response to the pandemic is building on multi-stakeholder initiatives such as the The COVID-19 Tool Access Accelerator (ACT-A) has essentially resulted in an international response driven by TNC interests rather than global solidarity.

As demonstrated in previous instances, the report says the COVID-19 pandemic has been a source of record profits for major pharmaceutical and biotech producers. Most strikingly, this suggests that the inclusion of TNCs in pandemic response mechanisms, in combination with their quest to protect and expand markets, has resulted in the prioritization of market opportunities over people’s lives.

In addition to issues around access to COVID-19 vaccines in the Global South, the report highlights examples of inequitable access to COVID-19 tests, personal protective equipment (PPE) and therapeutics – from Essential products highly inaccessible in developing countries due to prohibitive prices. Also among those products is medical oxygen, which about 15% of all COVID-19 patients need while on treatment, according to the nonprofit organization PATH.

In low- and middle-income countries, this translates to around 500,000 people needing a million cylinders of oxygen every day, an amount that exceeds what was defined in contracts signed before the start of COVID-19. . Since the start of the pandemic, oxygen shortages have been recorded in Jordan, Nigeria, Pakistan and Zimbabwe, among others. And although the shortages presented a direct threat to the health and lives of thousands of people in the Global South, some oxygen producers continued to insist on contractual clauses prohibiting the supply of oxygen from other sources. sources, including local extraction.

Among other things, ACT-A was supposed to examine and close the gaps between oxygen supply and need through an emergency task force coordinated by Unitaid, an intergovernmental funding agency, and the Wellcome Foundation based United Kingdom. But instead of developing approaches that would ensure rapid and accessible deployments of supplemental oxygen supplies when needed, the task force “focused on arranging grants and loans from OECD countries, from the World Bank, regional development banks and private foundations to enable local health authorities to purchase supplemental oxygen.

According to the report, there is concern that a similar procedure may have been put in place with regard to the purchase and distribution of PPE through ACT-A. A strategic plan from October 2021 to October 2022 remains silent on the more practical aspects of delivering PPE to the 92 priority countries. Reviewing the oxygen supply experience, the report states that it is “reasonable to assume that this objective and the related market expansion would be achieved, if at all, by increased debt or grants to institutions in developing countries”.

As Gleckman pointed out at the launch, this is a well-known pattern of the COVID-19 vaccine procurement process: countries that lacked the resources to pay the high prices set by producers vaccines were forced to take out loans around the world. Bank and the International Monetary Fund. This means that they will have to allocate even more money to debt service instead of strengthening health and social security systems, which will compromise their ability to respond to future crises.

Due to the effects of loans from international financial institutions on the stability of health systems in developing countries, debt and debt cancellation should be a major focus in future phases of the COVID-19 discussion, suggested Lauren Paremoer. With this element missing from the conversation, developing countries face the same grim no-access scenario they faced in the case of vaccines.

Read more articles from the latest edition of the People’s Health Dispatch and subscribe to the newsletter here.

read more
Generic drugs

Global Generic Drugs Market Report (2022-2027): Low Cost of Generic Drugs Compared to Branded Drugs and Robust M&A Activities in Generic Drugs Market Driving Growth – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Generic Drugs Market (2022-2027) by Category, Applications, End User, Geography, Competitive Analysis and Covid-19 Impact with Ansoff Analysis” report has been added to from ResearchAndMarkets.com offer.

The global generic drugs market is estimated at USD 374.14 billion in 2022 and is projected to reach USD 631.58 billion by 2027, growing at a CAGR of 11.04%.

Market segmentation

The global generic drugs market is segmented on the basis of category, applications, end-user, and geography.

  • By category, the market is categorized into biosimilars and generics of small molecules.

  • By applications, the market is categorized into Anti-Arthritis Drugs, Anti-Cancer Drugs, Anti-Infection Drugs, Cardiovascular Drugs, Central Nervous System Drugs, and Respiratory Drugs.

  • By end-user, the market is categorized into pharmacies, hospitals, pharmacies, private clinics, and retail pharmacies.

  • By geography, the market is categorized into Americas, Europe, Middle East & Africa, and Asia-Pacific.

Countries studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)

  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)

  • Middle East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)

  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and assess the position of companies based on their industry position score and market performance score. The tool uses various factors to classify players into four categories. Some of these factors considered for analysis are financial performance over the past 3 years, growth strategies, innovation score, new product launches, investments, market share growth, etc

Ansoff analysis

The report presents a detailed analysis of the Ansoff matrix for the global generic drugs market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design business growth strategies. The matrix can be used to assess approaches in four strategies viz. Market development, market penetration, product development and diversification. The matrix is ​​also used for risk analysis to understand the risk associated with each approach. The analyst analyzes the global generic drugs market using the Ansoff Matrix to provide the best approaches a company can take to improve its position in the market. Based on the SWOT analysis done on the industry and industry players, the analyst has designed appropriate strategies for market growth.

Why buy this report?

  • The report offers a comprehensive assessment of the global generic drugs market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and market size projections. Projections are calculated using proven research methodologies.

  • The report has been compiled through extensive primary and secondary research. The main research is done through interviews, surveys and observations of renowned personnel in the industry.

  • The report includes in-depth market analysis using Porter’s 5 forces model and Ansoff’s matrix. Additionally, the impact of Covid-19 on the market is also presented in the report.

  • The report also includes the regulatory scenario in the industry, which will help you to make an informed decision. The report discusses the major regulatory bodies and major rules and regulations imposed on this industry across various geographies.

  • The report also contains competitive analysis using Positioning Quadrants, the analyst’s proprietary competitive positioning tool.

Report Highlights:

  • A comprehensive analysis of the market, including the parent industry

  • Important market dynamics and trends

  • Market segmentation

  • Historical, current and projected market size based on value and volume

  • Market shares and strategies of the main players

  • Recommendations for companies to strengthen their presence in the market

Market dynamics

Drivers

  • Low cost of generic drugs compared to brand name drugs

  • Robust M&A activity in the generic drug market

  • Growing incidences of chronic diseases

Constraints

  • Strong commercialization of brand name drugs eclipses generic drugs

Opportunities

  • 3D manufacturing technology boosts

  • Increase collaboration on generic drug research

Challenges

  • Inactive ingredients or excipients are different

Main topics covered:

1 Description of the report

2 Research methodology

3 Executive Summary

4 Market dynamics

5 Market Analysis

6 Global Generic Drugs Market, by Category

7 Global Generic Drugs Market, by Applications

8 Global Generic Drugs Market, By End User

9 Americas Generic Drugs Market

10 European Generic Medicines Market

11 Middle East & Africa Generic Drugs Market

12 APAC Generic Drugs Market

13 Competitive landscape

14 company profiles

15 Appendix

Companies cited

  • Abbott Healthcare Pvt. ltd.

  • Allergan PLC

  • Amneal Pharmaceuticals, Inc.

  • Aspen Pharmacare Holdings Ltd.

  • Aurobindo Pharma Ltd.

  • Baxter International Inc.

  • Cipla inc.

  • Eli Lilly and company

  • Endo Pharmaceuticals Inc.

  • Fresenius medical care

  • GSK-API

  • Apotex Inc.

  • Lupine Ltd.

  • Mylan AG

  • Novartis International

  • Pfizer Inc.

  • Sandoz International GmbH

  • STADA Arzneimittel AG

  • Sun Pharmaceutical Industries Ltd.

  • Teva Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/6dznz2

read more
Prescription drugs

Navigating High Prescription Drug Prices

Steven and Jenna Emerson are the two faces of type 1 diabetes. They need thousands of dollars in drugs and supplies to stay alive.

“I would say $15 to $30,000 a year, depending on the year,” said their mother, Kelly Emerson.

That’s what the Emerson family pays after the insurance.

“Some days you have to rob Peter to pay Paul so you can afford to keep your kids alive,” she said. “When you have a child who is sick or needs medicine, you do whatever you have to do, and they know it.”

Emerson answers calls from creditors, chooses one need over another, and manages to keep his house whole. She is one of more than 100 million Americans working to cover up what will save someone’s life.

Marta Wosinska has spent more than two decades studying drug pricing and policy. She says prices are dictated by a web of interests that aren’t always aligned with those in need.

“Insurance companies are responsible for designing insurance benefits. List prices for drugs are set by pharmaceutical companies. Pharmacy benefit managers negotiate discounts, but they work for insurance companies,” Wosinska said. “Employers are the ones who select which plans to offer, often focusing on those that cost them the least.”

Wosinska said everyone has an incentive to embrace a system that sometimes works against them, with no federal solution in sight. But a partial answer may come from an unlikely source: nonprofit drug companies. They are popping up all over the country and competing with big pharma.

Allan Coukell is Senior Vice President at Civica RX. It’s one of many companies making deals with hospitals and winning federal grants. They are trying to create competition and ultimately drive down the price of generic drugs.

“Our first drug will actually launch this summer. Our insulins will hit the market in early 2024. And our goal is to make them available through a variety of mail-order channels and brick-and-mortar pharmacies,” Coukell said.

In the meantime, Emerson continues to search for elusive relief. Until then, she says, she will continue to answer calls from creditors, make tough decisions and take nothing for granted.

“You never know what the future holds. Things can change in no time,” she said. “But I want to give my children the best opportunity to live their best life.”

read more
Prescription drugs

Sue Menegat: Making prescription drugs affordable |

SUE MENEGAT

A recent editorial by Drew Johnson (Missoulian July 27) demonstrates that a barking dog can’t bite when it has false teeth, and Johnson’s statistics are ill-fitting dentures. With strategically played stats, anyone can twist a topic from their own point of view, especially if they have an agenda. Mr Johnson’s agenda appeared to be for “Big Pharma” and against improving health care for Americans. Statistics are everywhere – any statistic one wants to prove any desired point, whether accurate or not, can be found. The problem is that statistics are flexible, but facts are stubborn things. The truth will come out.

The statistics I found in a quick Google search point to a different conclusion than Mr. Johnson. One set, from the Kaiser Foundation, notes that, since 2014, drug prices have increased by 35% compared to a much smaller price increase of 19% for all other products. Another set of statistics, that of the AMA, points out that between 2008 and 2021, the cost of each newly introduced drug has increased by 11% per year. And a Medicare study found that the price of half of all drugs rose faster than the rate of inflation.

People also read…

Johnson is trying to dissuade readers from supporting President Biden’s Build Back Better plan, which would increase funding for Medicaid and allow Medicare to negotiate drug prices with “Big Pharma.” The reasons for the changes proposed by the President are simple; 90% of seniors and 50% of adults take prescription drugs, and 18 million Americans cannot afford their medications. Another 118 million people cannot afford health care, let alone insurance – ahhh, statistics again. Let’s make it more personal. People who can’t afford the necessary health care and necessary medication live shorter lives, can get sick and sometimes die Yes, people are dying.

Think of older couples who split pills into 2 or 3 to reduce drug costs. How about the woman who asks her pharmacist to fill only 1/4 of her prescription because she can’t afford the cost of $270/month. (Others pay $0 to $4 through insurance.) Think Lisa Ann. After seeing insulin prices rise every year, she tried to increase the doses, but was reluctant to tell anyone about her situation. She worked two jobs all her life, but had no drug coverage. She died, alone, of insulin shock at the age of 60. Or think of Jan. She had lower back pain and thought it was a bad disc from lifting heavy things at work. Years before, a non-cancerous cyst had been removed from her neck. After that, her husband’s insurance classified her as having a “pre-existing condition” and declined additional coverage (this was before Obamacare). She postponed her visit to the doctor, waiting to be eligible for Medicare, after all, it was a disc problem. But that was not the case. Jan died of colon cancer four months before her 65th birthday.

A death is a tragedy; a million deaths is a statistic, and statistics erase names. Millions of people are in the same boat, and they all have names. Johnson calls Democrats socialists because they want all Americans to have access to health care. Yet, in reality, various federal, state, and local government programs and policies are, by definition, socialist…the public school system, state universities, national parks and national forests, the military, the AV, police and firefighters, Social Security, Medicaid and Medicare, agricultural subsidies, oil subsidies, all paid for in a “socialist” way by our taxes. All were proposed and instituted by Republicans and Democrats. Slinging tags and calling names is useless and doesn’t solve any problems.

Yes, the poor are and will always be with us. But our society has the means to lighten people’s burdens. Why do prescriptions for Americans cost so much more than the same drug in Canada, Mexico, European countries and for the VA? Why is the life expectancy of Americans ranked 46th among the nations of the world?

If billionaires can spend their money building spaceships just to personally experience weightlessness, Americans can solve our health care debacle. Mr. Johnson, can’t America, the land of the free and the brave, afford to build back better? There, but for the grace of God, I go, or any of us.

Sue Menegat is a retired historian and special education teacher. She volunteers at the Missoula Senior Center.

You must be logged in to react.
Click on any reaction to connect.
read more
Medical supplies

Gambia: WHO hands over medical supplies and equipment to Moh

The World Health Organization (WHO) handed over medical supplies and equipment to the Ministry of Health last Friday during a handover ceremony held at the Central Medical Store in Kotu.

Items vary in size and value and include surgical masks and disposable gloves, triple-wrapped insulated cryobox and freezer boxes. The items, hailing from various countries, namely China, India and the United Arab Emirates, cost more than two hundred and seventeen thousand dollars (US$217,000).

Welcoming the gathering, Babanding Sabally, director of pharmaceutical services at the ministry, reiterated that quality health services mean availability of essential drugs and medical products.

He praised the WHO for its consistent support since the start of the pandemic, acknowledging that the UN agency has also played a crucial role in advocating for support from other partners to complement the government in the fight against the disease. pandemic.

“Our partners are aware of this fact and therefore they always come to our aid to complement whatever the government is doing.”

The UN agency, he added, has been supporting the country’s health care sector not only technically, but by providing much-needed financial support to the country.

Introducing the papers, Dr Desta Tiruneh, WHO Representative to The Gambia, recalled that with the onset of the Covid-19 pandemic, the past few years have been a difficult journey for people in The Gambia and around the world. .

He observed that since the start of the pandemic, WHO has worked in tandem with the government, the United Nations system, the private sector and multilateral and bilateral partners to support the development and implementation of a strong strategy and guidelines for the response to the pandemic.

“The close collaborative partnerships we have fostered have fostered a rapid scale-up of the pandemic response in the country and helped us cushion the drastic blow of Covid-19.”

Dr Tiruneh described that the event was not only a celebration of such fruitful partnerships across sectors, but also a move to further cement the relationship in a demonstration of shared commitment to improving public health in The Gambia. .

“I would like to take this opportunity to sincerely thank our esteemed partners for their continued support of WHO’s emergency work in The Gambia. In particular, we would like to thank our most generous partners, including the governments of the United Kingdom, from Canada, the United States, Germany, France, the Netherlands and Azerbaijan.”

On receiving the articles, Dr Ahmad Lamin Samateh, Minister of Health, hailed the long-standing partnership between the Gambian government and WHO.

This mutual partnership, he noted, is growing stronger, recognizing that the WHO, as a global leader in the health sector, has truly done its job as expected by the peoples of the world.

“All over the world, there must certainly be coordination of every activity of life, otherwise countries and people will have their own notions, norms and ways of doing things. But we are lucky to have an institution like the WHO which harmonizes all of this and sets out benchmarks that countries could use as standards and guidelines to measure performance, productivity and all the parameters that need to be measured.”

The WHO office in The Gambia, Minister Samateh acknowledged, has really fulfilled this role, adding that since the start of the Covid-19 pandemic, the WHO country office and the entire United Nations system in The Gambia have worked harmoniously exchanging ideas to ensure that the country responds adequately to Covid-19.

read more
Medical supplies

Research Segments by Global Emergency Medical Supplies Market Size, Industry Trends, Share and Forecast 2022-2028 | Bound Tree Medical, Henry Schein, Inc.

Emergency Medical Supplies Market

The recent research report on Global Emergency Medical Supplies Market 2022-2028 explains current market trends, possible growth rate, differentiable industry strategies, future prospects, significant players and their profiles, regional analysis and industry shares along with forecast details. The detailed study offers a wide range of considerable information which also emphasizes the significance of key parameters of the global Emergency Medical Supplies Market.

The emergency medical supplies market is expected to grow at a CAGR of 16% during the forecast period.

Click Here For Free Sample PDF Copy Of Emergency Medical Supplies Market 2022 Latest Research Before Purchase: @ https://www.theresearchinsights.com/request_sample.php?id=531281&mode=07RJ

Top Key Players are covered in this report:

Bound Tree Medical, Henry Schein, Inc., McKesson Medical-Surgical, Inc., Medline Industries, Inc., Stryker Corporation, Emergency Medical Products, Inc., Cardinal Health, Smiths Medical, Inc., Life-Assist, Medtronic plc. among others.

On the basis of product, the emergency medical supplies market is primarily split into:

By Product (Life Support and Emergency Resuscitation, Patient Monitoring Systems, Wound Care Consumables, Patient Treatment Equipment, Infection Control Supplies, Other EMS Products)

KBased on end users/application, this report covers

N / A

Market segment by region/country comprising:

Asia Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America[United States, Canada, Mexico]
Middle East and Africa[GCC, North Africa, South Africa]
South America[Brazil, Argentina, Columbia, Chile, Peru]

Key Highlights of the Emergency Medical Supplies Market report study:
• A detailed overview of the global emergency medical supplies industry
• The report analyzes the global emergency medical supplies market and provides its stakeholders with important actionable insights
• The report has considered all the major developments in the recent past, helping the users of the report with the latest industry updates
• The study of the report should help the key decision makers in the industry to help them in the decision-making process
• The study includes data on Emergency Medical Supplies market intelligence, changing market dynamics, current and forecasted market trends, etc.
• The report includes an in-depth analysis of macroeconomic and microeconomic factors affecting the global emergency medical supplies market
• Market ecosystem and adoption in all market regions
• Key trends shaping the global emergency medical supplies market
• Historical and forecast size of the emergency medical supplies market in terms of revenue (USD Million)

SPECIAL OFFER: GET UP TO 30% OFF THIS REPORT: https://www.theresearchinsights.com/ask_for_discount.php?id=531281&mode=07RJ

The Emergency Medical Supplies Market report provides a primary review of the industry along with definitions, classifications, and the form of the business chain. Market analysis is provided for global markets which includes improving trends, assessment of hostile views and development of key regions. Development policies and plans are discussed in addition to manufacturing strategies and royalty systems are also analyzed. This file also indicates import/export consumption, supply and demand, expenses, sales and gross margins.

Browse the full report at:https://www.theresearchinsights.com/reports/global-emergency-medical-supplies-market-growth-2022-2028-531281?mode=07RJ

Research covers the following objectives:
– To study and analyze the global Emergency Medical Supplies consumption by key regions/countries, product type and application, history data from 2016 to 2022, and forecast to 2026.
– To understand the structure of Emergency Medical Supplies by identifying its various subsegments.
– Focuses on the key global Emergency Medical Supplies manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, Five Forces Analysis of Porter, SWOT analysis and development plans over the next few years.
– To analyze the Emergency Medical Supplies with respect to individual growth trends, future prospects, and their contribution to the total market.
– Share detailed information about key factors influencing market growth (growth potential, opportunities, drivers, industry-specific challenges, and risks).
– To project the consumption of Emergency Medical Supplies submarkets, with respect to key regions (along with their respective key countries).
Report customization:
Emergency Medical Supplies, the report can be customized to suit your business needs as we recognize what our customers want, we have extended customization by 25% at no additional cost to all of our customers for any of our syndicated reports .
In addition to customizing our reports, we also offer fully customized research solutions to our clients across all industries we track.
Our research and insights help our clients identify compatible business partners.
To note: All of the reports we list tracked the impact of COVID-19 on the market. In doing so, the upstream and downstream flows of the entire supply chain have been taken into account. Additionally, where possible, we will provide an additional COVID-19 update report/supplement to the Q3 report, please check with the Commercial team.

About Us:
The Research Insights – A world leader in analysis, research and advice that can help you renew your business and change your approach. With us, you will learn to make decisions without fear. We make sense of disadvantages, opportunities, circumstances, estimates and information using our experienced skills and verified methodologies. Our research reports will give you an exceptional experience of innovative solutions and results. We have effectively led businesses around the world through our market research reports and are in an excellent position to lead digital transformations. Therefore, we create greater value for customers by presenting advanced opportunities in the global market.

Contact us:
robin
Commercial director
Contact number: +91-996-067-0000
[email protected]
https://www.theresearchinsights.com

read more
Medical products

Kenya and Novo Nordisk sign MoU to provide medical products to children with diabetes

The Government of Kenya and Novo Nordisk, a Danish multinational pharmaceutical company, have signed a memorandum of understanding for the supply of medical products to improve the treatment and self-management of type 1 diabetes in children.

Speaking at the ceremony, Cabinet Secretary for Health Mutahi Kagwe said the long-term aspiration of the program was not only to improve the lives of children enrolled in the project, but also to find ways to integrate the components of the program into the delivery of health care in the country.

He said the parties have entered into a partnership to use their respective skills and strengths to improve the well-being of people living with diabetes in Kenya through sustainable partnerships and collaborations, as well as to improve the diabetes care for children with type 1 diabetes in Kenya. the country.

“We welcome you and thank you for your support. Your partnership is important and we value it. We invite you to think about investing in the country in terms of manufacturing,” said the Health CS.

To reach more children with diabetes, Kenya needs to establish additional type 1 diabetes clinics and build the capacity of health workers, with Novo Nordisk committing two billion shillings to support the program for the next 3 years.

The two parties have agreed on how to improve and establish the infrastructure of diabetes clinics and the provision of medical and laboratory equipment, training and education of health professionals working on diabetes in type 1 in children and adolescents, the provision of human insulin and blood glucose monitoring equipment and supplies at no cost to children and adolescents. They also agreed to educate children and teens with type 1 diabetes and their families, create a registry for children and teens with type 1 diabetes, and share ideas and results for improvement. Continuation of the Changing Diabetes in Children Project between parties. .

In the agreement, the Government of Kenya will be obliged, among other things, to gradually integrate the Changing Diabetes in Children program into the national health system and to ensure that diabetes and specifically type 1 diabetes is included in the national non-communicable disease agenda. consistent with the Sustainable Development Goals.

Novo Nordisk, in turn, will have to provide the diagnostic, screening and monitoring equipment necessary for the organization and operation of diabetes clinics and the patient registry, provide free human insulin to cover diabetes treatment needs type 1 in children and adolescents up to 25 years old in the health structures supported by the CDiC project.

The company will also have to support the training of health professionals in the management of type 1 diabetes in children and adolescents, support awareness campaigns in collaboration with various stakeholders, support education on diabetes self-management for children, adolescents and their families, including development The CDiC project provides educational materials to patients and supports the improvement of infrastructure in some of the diabetes clinics, as determined by the ministry of Health.

The MoU was signed by Vinay Ransiwal, Managing Director and Vice President on behalf of Novo Nordisk and CS Mutahi Kagwe on behalf of the Government of Kenya and in the presence of Danish Ambassador to Kenya Ole Thonke.

The Changing Children’s Diabetes program was launched in Kenya in 2012 to ensure that children with type 1 diabetes have access to appropriate treatment and support. The partnership was between Novo Nordisk, the Government of Kenya, Roche Diabetes and the Kenya Diabetes Management and Information Center (DMI). It was created to identify solutions that can lead to an integrated approach to the diagnosis, treatment and control of diabetes in children with type 1 diabetes.

(With contributions from APO)

read more
Medical supplies

Darlington man Ken Longstaff struggles to get NHS medical supplies

The wife of a man who needs round-the-clock care after being struck down with a rare disease has raised concerns after struggling to get the medical supplies he needs to stay alive.

Ken Longstaff, of Darlington, depends on care for his daily needs after being diagnosed with Guillain Barre syndrome in 2012.

The condition left him locked up for seven weeks and the 64-year-old, who has discovered a talent for art since his diagnosis, is now confined to a wheelchair and requires round-the-clock care.

Read more: How good is it? Brilliant mural appears in Darlington to celebrate women’s football

His wife Beverley, 62, has raised concerns about obtaining essential medical supplies for the past six months via the Darlington District Nursing Team, through whom she is believed to be able order them.

County Durham and the Darlington NHS Foundation Trust, which is leading the team, said global logistics issues were having a “significant impact” on the supply of some items in the North East – but decided to reassure patients that the trust was working to ensure patients were never deprived of essential equipment.

Ken Longstaff of Darlington

Mrs Longstaff wants to raise awareness of the issue after struggling to get replacement tubes for her husband’s tracheostomy, which he needs to help him breathe, as well as a special type of essential water for his ventilator , which he needs at night .

He usually keeps a spare game in his bag, which accompanies him everywhere, as well as two at home.

However, the couple struggled to replace the kit as it is used and recently recorded backup compliance due to difficulty obtaining the tracheostomy tube.

She said: “I had an incident where they said they couldn’t have a tracheotomy. I kept trying and trying, then they sent me one that was completely different.

“We got to the stage about a week ago where we only had one left, which is the one he wears all the time.”

Recalling an incident last week, she said she was called at 5 a.m. by her carer to help as he was struggling to breathe.

After being unable to clear her airway by suction, she feared having to use the unknown tracheotomy, and would then find herself in a position where she would have no reserve in case of another emergency. Fortunately, after several attempts, they managed to clear the airways.

She added: “My problem is that if we were to use the other one and it hadn’t worked, I would have a dead man on my hands.”

Darlington and Stockton Times: Ken Longstaff has discovered a talent for art since his diagnosis Ken Longstaff has discovered a talent for art since his diagnosis

Mrs. Longstaff, who works as a receptionist at Woodland Hospital, at Darlington, spent several days last week trying to get supplies, which she managed to get to intensive care from James Cook University Hospital, Middlesbrough and Darlington Memorial Hospital.

To get more Darlington stories straight to your email basket, click here

She said, “The only reason we have them is because I begged and borrowed and stole from other people. I got them from the intensive care units, but that means they no longer have those supplies.

“There will be people like us who will struggle to get supplies and they won’t have the contacts we have.”

She added: “We’re lucky because where I work I have contacts. What about an OAP who doesn’t know who to ask for help? danger.

“It shouldn’t be something I deal with at all. People need to know that’s a problem.

A spokesperson for County Durham and Darlington NHS Foundation Trust, said: “The current global manufacturing and logistics issues are having a significant impact on the supply of certain clinical and other items across the NHS. We are working closely with the NHS supply chain to find alternative products if needed.

“Our patients always come first and we fully understand Mr Longstaff’s family’s concern that certain equipment is not currently as readily available as it once was and we apologize for the concern this has caused them. We are in close contact with Mr. Longstaff’s family to ensure they have the equipment he needs.

Read next:

If you want to read more great stories, why not subscribe to your Northern Echo for as little as £1.25 a week. Click here

read more
Medical products

Physical testing for 3D printed medical products

Image Credit: Stable Micro Systems Ltd

3D printing has become a niche manufacturing method, allowing consumers to design and manufacture their own products. As such, it now occupies an important place in the manufacturing industry. Objects can be constructed in almost any format the consumer desires, and this has overcome the early limitations of certain groups of polymers as a building material. It’s now a potential tool in many industries, including bone and organ replacements, meat manufacturing, and even customizable baking.

Stable Micro Systems manufactures instruments that measure the tensile and compressive properties of 3D printed parts. As with any manufacturing innovation, the final product must go through a quality control process to assess its physical properties. A Texture Analyzer is a crucial part of this procedure, providing a reliable way to test the mechanical properties of 3D printed objects by applying a choice of compression, tension, extrusion, adhesion, bending or cutting tests to measure the resistance of a product physical properties for example tensile strength, flexural modulus, fracturability, compressibility, to name but a few.

3D Printing Materials Test Example – Extrusion

The printability of materials used in extrusion 3D printing is one of the most important properties, especially when manufacturing objects with architectural complexities. This parameter is influenced by several factors (temperature, components and additives), which makes a thorough evaluation and classification difficult. Interest in 3D printing for biomedical applications is growing and the pharmaceutical industry is beginning to explore how 3D printing can help us deliver better medicines. Achieving reproducibility in 3D printing of biomaterials requires a robust polymer synthesis method to reduce batch-to-batch variation as well as methods to ensure thorough characterization throughout the manufacturing process. In particular, biomaterial inks containing large solid fractions such as ceramic particles, often required for bone tissue engineering applications, are prone to inhomogeneity from improper mixing or particle aggregation which can lead to inconsistent print results. The production of such ink can be optimized to ensure consistent and repeatable print results by using a TA.XTPlusC Texture Analyzer to perform extrusion force measurements to predict the printability of inks. To read a sample post of this texture analyzer app at ETH Zurich, Click here.

Direct extrusion test on a texture analyzer. Image Credit: Stable Micro Systems Ltd

3D Printing Materials Test Example – Compression

Due to the low price of 3D printing equipment and its versatility, materials such as antioxidant PLA composites containing lignin can be used in hospitals to print dressings for patients on demand. 3D printing can also benefit plastic and reconstructive surgeries by fabricating patient-specific tissue substitutes with tissue-like functions and mechanical properties. A texture analyzer can be used to perform compression test on samples to characterize their mechanical properties which are important for their structural integrity. To read a sample post of this Texture Analyzer app at the University of Nottingham, Click here.

Unconfined compression on a texture analyzer. Image Credit: Stable Micro Systems Ltd

3D Printing Materials Test Example – Bending and Bending

3D printing offers a new approach to the fabrication of drug-eluting implantable medical devices, as it allows complex and custom shapes of tissue scaffolds to be flexibly extruded. Given the simplicity, it can be easily transferred to a clinical setting, where implants could be designed on demand to meet patient needs after surgery. These implants may be suitable for administering drugs for localized treatment. For example, chemotherapy agents, antibiotics or local anesthetics. Alternatively, they could be adapted by coating them for prolonged administration of drugs for the treatment of chronic diseases.

Compared to other printable biomaterials, polyurethane elastomers have several advantages, including excellent mechanical properties and good biocompatibility. However, some intrinsic behaviors, especially high melting point and slow degradation rate, hinder their application in 3D printed tissue engineering. The development of a 3D printable amino acid modified biodegradable water-based polyurethane means that the flexibility of this material provides better tissue compliance during implantation and prevents high modulus grafts from scratching tissue surrounding. The use of a texture analyzer to perform flexibility measurements (three-point curvature) on 3D printed samples allows to evaluate if this can be used as an alternative biomaterial for tissue engineering with low temperature printing, biodegradability and compatibility. To read a sample post of this texture analyzer app at Beijing Science and Technology University, Click here Where Click here to see similar work at Queen’s University Belfast.

3-point flexibility and bending test on a texture analyzer. Image Credit: Stable Micro Systems Ltd

Example of testing 3D printing materials – Perforation, Elongation and Tension:

Orodispersible films (ODF) are promising dosage forms for children or the elderly who may have swallowing problems with solid oral dosage forms. By printing active pharmaceutical ingredients on orodispersible films, the flexibility of drug dosing is increased and offers potential for personalized drugs. Warfarin is an example of a drug with a narrow therapeutic index which requires a personalized dosage which is not currently achieved by marketed products. 3D printing by extrusion can be used to produce transparent, smooth and thin, yet flexible and resistant orodispersible films containing therapeutic doses. Using a texture analyzer, films can measure their properties of burst strength and flexibility as part of their critical physical characteristics that could impact their usability.

To read a sample post of this texture analyzer app at Heinrich Heine University Dusseldorf Click hereWhere Click here for similar work done at Åbo Akademi University.

Bursting strength, tensile strength and film flexibility on a texture analyzer. Image Credit: Stable Micro Systems Ltd

How a Texture Analyzer Can Assess the Flow of Base Powder

Texture analysis can also be used at other stages of the 3D printing process, not just to measure the properties of the final product. For example, the properties of the base powder used in selective laser sintering affect the sintering process as well as the properties of the final product. The flow of the powder is one of these properties. As each new layer of powder is swept over the sinter bed, the layer should be even and of the correct thickness and distribution. A Powder flow analyzer (PFA) is a very useful addition to a Texture Analyzer Plus to help measure these flow properties.

PFA proves to be an accurate and reliable method for measuring the flow characteristics of dry and wet powders, with the ability to measure cohesion, clumping and velocity flow dependence as well as bulk density and other properties. It can be quickly retrofitted to a TA.XTPlusC Texture Analyzer, allowing manufacturers to assess and avoid typical issues such as batch and source variation of ingredients, clumping during storage/transportation and problems unloading hoppers or bins, as well as 3D printing. specific properties of the powder. The powder is conditioned at the start of each test to eliminate any load variation and the patented precision blade is then rotated through the sample causing a controlled flow.

Image Credit: Stable Micro Systems Ltd

The need to measure dimensional profiles

If you designed a product and then print it, one of the concerns will be whether what was printed matches what you designed. In many cases you will need your printed object to be dimensionally accurate and printing iterations of your design are almost inevitable to adjust the print settings to achieve a dimensionally accurate product. A precise numerical evaluation of the physical dimensions thus becomes a necessity. A Volscan Profiler provides such a solution – a benchtop laser scanner that measures the volume, density and dimensional profiles of solid products. Rapid three-dimensional scanning of products allows for the automatic calculation of several detailed dimension-related parameters, the results of which can be mathematically manipulated for immediate use or future retrieval in a variety of data formats for your printed objects.

Volscan Profiler models for measuring volume, density and dimensional profiles. Image Credit: Stable Micro Systems Ltd

Bone sample ready for scanning and an archived scan of the sample. Image Credit: Stable Micro Systems Ltd

The medical industry is increasingly dependent on the TA.XTmoreC Texture Analyzer as a tool for measuring all types of physical/mechanical properties.

See a wider range of test and measurement possibilities in this area.

read more
Prescription drugs

Prescription Hyperlipidemia Drugs Market Size by Share, Growth and Forecast 2029 – Instant Interview

Global Prescription Drugs for Hyperlipidemia Market is expected to grow at a CAGR of 14.50% to reach USD xx million through 2029

Overview of the Prescription Drugs for Hyperlipidemia Market

Prescription Drugs for Hyperlipidemia research report includes all the necessary details. By providing accurate data to its clients, it helps them make important decisions and gives market forecasts. This study, which combines primary and secondary research, provides market size, share, trends and forecasts for important segments and sub-segments. This market research monitors all the latest developments and changes in the industry. It provides information on the obstacles encountered when starting a business and offers advice on how to deal with impending difficulties.

Download a sample exclusive report:

https://pharmaresearchconsulting.com/reports/hyperlipidemia-prescription-drugs-market-global-growth-trends-and-forecast-2022-2029-by-type-hmg-coa-reductase-inhibitors-fibric-acid-derivatives- nicotinic-acid-by-hospital-clinical-application-and-by-regions/demand

Report scope

The research analysis of the Global Prescription Drugs for Hyperlipidemia Market takes a close look at the market size, trends, and potential opportunities. By offering in-depth details of technology expenditure for the projection year, this research provides a unique perspective on the global Prescription Hyperlipidemia Drugs market across various categories. Clients can learn more about the potential and limitations of the industry by reading the study on the Global Prescription Drugs for Hyperlipidemia Market. The study discusses in detail a number of factors that have been identified as influencing the growth trajectory of the market. The issues facing the market are also identified in the study.

Key companies influencing this market include:

Amgen, are Eli Lilly, GlaxoSmithKline Pharmaceuticals, Isis Pharmaceuticals, Merck, Dr. Reddy’s Laboratories, Immuron Limited, Esperion Therapeutics and Pfizer, Formac Pharmaceuticals and others.

Global Prescription Hyperlipidemia Drugs Market Segmentation:

By Type, it is segmented into

  • HMG COA reductase inhibitors
  • Fibric acid derivatives
  • nicotinic acid
  • Bile acid sequestering agents
  • Cholesterol absorption inhibitors
  • Combination drug therapy

By Application, it is segmented into

Regional coverage:

The research mentions the regional scope of the market, mainly focusing on the following areas:

  1. North America (United States, Canada and Mexico)
  2. Europe (Germany, France, UK, Russia and Italy)
  3. Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
  4. South America (Brazil, Argentina, Colombia, etc.)
  5. Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, Nigeria and South Africa)

Buy a full copy of Prescription Drugs for Hyperlipidemia Market report:

https://pharmaresearchconsulting.com/reports/hyperlipidemia-prescription-drugs-market-global-growth-trends-and-forecast-2022-2029-by-type-hmg-coa-reductase-inhibitors-fibric-acid-derivatives- nicotinic-acid-by-hospital-clinical-application-and-by-regions.

Key information covered Hyperlipidemia Prescription drugs Market research:

  • Manufacturers Production Capacity Analysis of Prescription Hyperlipidemia Drugs
  • Key factors shaping the growth of the Prescription Hyperlipidemia Drugs Market
  • Hyperlipidemia Prescription Drugs Industry Segmentation Analysis
  • Competitive Mapping for Key Players in the Prescription Hyperlipidemia Drugs Market
  • Prescription Drugs for Hyperlipidemia Market Growth to 2029
  • Analysis of Direct and Indirect Sales of Prescription Drugs for Hyperlipidemia
  • Hyperlipidemia Prescription Drugs Industry Share 2022
  • Distribution Channel Analysis of Prescription Drugs for Hyperlipidemia

Contents:

Chapter 1: Introduction, Market Driver Product Research and Research Objectives Scope of Prescription Drugs for Hyperlipidemia Market

Chapter 2: Exclusive Summary – Basic Information on the Prescription Drugs for Hyperlipidemia Market.

Chapter 3: Revealing Market Dynamics – Drivers, Trends and Challenges

Chapter 4: Presenting the Porters Five Forces Prescription Hyperlipidemia Drugs Market factor analysis, supply/value chain, Pestel analysis, market entropy, patent/trademark analysis.

Chapter 5: View by Type, End User and Region 2022-2029

Chapter 6: Evaluation of the Prescription Drugs for Hyperlipidemia Market leading manufacturers including competitive landscape and company profiles

Chapter 7: To assess the market by segments, countries and manufacturers, with revenue sharing and sales by key countries for these various regions.

Chapters 8 and 9: Appendix, methodology and data source display

Contact us: –
Phone number+1 (704) 266-3234

Send mail to: [email protected]

read more
Prescription drugs

Board can make prescription drugs more affordable in New Mexico | My opinion

read more